Latest Regulatory Approval News

AuKing Mining has entered a strategic agreement with Gage Capital Management, raising $300,000 through a 60 million share placement and selling two Tanzanian prospecting licences, positioning the company for growth across multiple jurisdictions.

BlueBet has announced a strategic acquisition of TopSport, supported by a $15 million equity raise, aiming to boost market share and deliver significant earnings accretion by FY26.

Brookfield Capital Partners has submitted a non-binding proposal to acquire Insignia Financial at A$4.60 per share, matching rival offers and setting the stage for a competitive bidding process.

Hartshead Resources has submitted a revised development report to the NSTA, unveiling a superior gas export route through CalEnergy's Saturn Banks pipeline that promises reduced costs and faster production.

Solstice Minerals has secured the advanced Nanadie Copper-Gold Project in Western Australia, acquiring a JORC-compliant Inferred Mineral Resource of 40.4Mt at 0.4% copper and 0.1g/t gold. The acquisition positions Solstice for growth amid strong long-term copper demand.

A new peer-reviewed study highlights Cynata Therapeutics’ Cymerus™ iPSC-derived MSCs as superior to traditional donor tissue-derived MSCs in potency, consistency, and regenerative potential.

A1 Investments & Resources Ltd reported a modest cash outflow for the December quarter while actively pursuing acquisition opportunities backed by secured funding. The company aims to finalize a deal soon, contingent on shareholder and regulatory approvals.

AustChina Holdings has entered a binding agreement to acquire Penwortham Exploration, gaining access to promising gold-antimony and base metals projects in Tasmania’s prolific mining districts. The move positions AustChina to leverage modern exploration techniques on historically rich targets.

Rimfire Pacific Mining has confirmed the Currajong Prospect as a promising new high-grade scandium opportunity, supported by historic drill data. The company plans an extensive drilling campaign in early 2025 to further define this resource within its Fifield project portfolio.

OncoSil Medical has secured authorization for 120 German hospitals to negotiate funding for its pancreatic cancer treatment device, marking a 43% increase from last year and signaling growing acceptance in Germany’s healthcare system.

Cue Energy Resources has pushed back the deadline for its gas supply agreement with Arafura from early February to the end of March 2025, signaling a critical timeline shift for the Nolans rare earths project.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.